Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis

被引：87

作者：

Baraut, Julie ^{[1
]}

Michel, Laurence ^{[1
]}

Verrecchia, Franck ^{[3
]}

Farge, Dominique ^{[1
,2
]}

机构：

[1] Hop St Louis, INSERM, U976, F-75010 Paris, France

[2] Hop St Louis, Serv Med Interne, F-75010 Paris, France

[3] Univ Nantes Atlantique, INSERM, U957, F-44000 Nantes, France

来源：

AUTOIMMUNITY REVIEWS | 2010年 / 10卷 / 02期

关键词：

Systemic sclerosis; Cytokines; Fibrosis; T lymphocytes; REGULATORY T-CELLS; AUTOIMMUNE-DISEASES; PULMONARY-FIBROSIS; ORGAN INVOLVEMENT; SKIN SCLEROSIS; SERUM-LEVELS; SCLERODERMA; EXPRESSION; RECEPTOR; ASSOCIATION;

D O I：

10.1016/j.autrev.2010.08.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Although the pathogenesis of systemic sclerosis (SSc) remains unknown, cytokine production and release are key events in this autoimmune disease, characterized by T cell activation and auto-antibodies production leading to microvascular damage, inflammation and fibrosis. We review herein experimental and clinical data, aiming to analyze the relationship between cytokine release and SSc pathogenesis. Measurement of circulating or in situ cytokine levels provides evidence for a balance between "Th1/Th2" or "Th17/Treg" cytokines in the development of SSc. Indeed, the Th2 cytokine response, with the production of IL-4, IL-10 and TGF-beta, leads to tissue fibrosis, whereas Th1 and Th17 cytokines promote inflammation in SSc patients. Thus, cytokine levels have been assessed as diagnostic or prognostic markers in SSc patients. Restoration of the Th1/Th2/Th17/Treg balance is one of the hallmarks of treatment effectiveness and development of cytokine modulators could be considered for new therapeutic approaches in SSc patients. (c) 2010 Elsevier B.V. All rights reserved.

引用

页码：65 / 73

页数：9

共 60 条

[1] Scleroderma: from cell and molecular mechanisms to disease models [J].